← back to search

Jeffrey A. Cohen

Cleveland Clinic · US
Area of research
Pathology and Forensic Medicine · Neurology
Research interest
Research interests include Multiple Sclerosis Research Studies, Peripheral Neuropathies and Disorders, Sphingolipid Metabolism and Signaling, and Polyomavirus and related diseases.
h-index
82
citations
32,200
works
616
NIH funding
primary concept
email

Recent publications

Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria
The Lancet Neurology 2025cited by 254position: middledoi
Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder — recommendations from ECTRIMS and the EBMT
Nature Reviews Neurology 2025cited by 42position: middledoi
Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis
JAMA Network Open 2025cited by 15position: middledoi
Five-Year Safety and Efficacy Outcomes with Ofatumumab in Patients with Relapsing Multiple Sclerosis
Neurology and Therapy 2025cited by 9position: middledoi
Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension
Multiple Sclerosis Journal 2023cited by 45position: middledoi
Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis
Multiple Sclerosis and Related Disorders 2023cited by 19position: middledoi
Multiple sclerosis progression: time for a new mechanism-driven framework
The Lancet Neurology 2022cited by 587position: middledoi
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial
The Lancet Neurology 2022cited by 109position: middledoi
Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II
Multiple Sclerosis Journal 2022cited by 95position: middledoi
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial
Multiple Sclerosis Journal 2022cited by 47position: lastdoi
Women's Health in Multiple Sclerosis: A Scoping Review
Frontiers in Neurology 2022cited by 24position: middledoi
Primary Results of NOVA: A Randomized Controlled Study of the Efficacy of 6 Week Dosing of Natalizumab Versus Continued 4-Week Treatment for Multiple Sclerosis
Multiple Sclerosis and Related Disorders 2022cited by 3position: middledoi
Central vein sign: A diagnostic biomarker in multiple sclerosis (CAVS-MS) study protocol for a prospective multicenter trial
NeuroImage Clinical 2021cited by 59position: middledoi
Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis
Multiple Sclerosis Journal 2021cited by 14position: middledoi
Advances in oral immunomodulating therapies in relapsing multiple sclerosis
The Lancet Neurology 2020cited by 112position: middledoi
COVID-19 in people with multiple sclerosis: A global data sharing initiative
Multiple Sclerosis Journal 2020cited by 61position: middledoi
Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis
Multiple Sclerosis and Related Disorders 2020cited by 21position: middledoi
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial
The Lancet Neurology 2019cited by 283position: lastdoi
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial
The Lancet Neurology 2019cited by 277position: firstdoi
Evaluation of multiple sclerosis disability outcome measures using pooled clinical trial data
Neurology 2019cited by 93position: lastdoi
Evaluating the efficacy and safety of 6-week extended interval dosing of natalizumab via a prospective, controlled, randomized, open-label, rater-blinded phase 3b study (P3.2-095)
Neurology 2019cited by 3position: middledoi
Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers
Neurology Clinical Practice 2018cited by 29position: middledoi
Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis
Multiple Sclerosis Journal 2017cited by 399position: middledoi
The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability
Multiple Sclerosis Journal 2017cited by 64position: middledoi
Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up
Multiple Sclerosis Journal - Experimental Translational and Clinical 2017cited by 42position: middledoi
Recommendations for observational studies of comorbidity in multiple sclerosis
Neurology 2016cited by 81position: middledoi
The challenge of comorbidity in clinical trials for multiple sclerosis
Neurology 2016cited by 60position: middledoi
Effect of Template Reporting of Brain MRIs for Multiple Sclerosis on Report Thoroughness and Neurologist-Rated Quality: Results of a Prospective Quality Improvement Project
Journal of the American College of Radiology 2016cited by 58position: middledoi
The incidence and prevalence of psychiatric disorders in multiple sclerosis: A systematic review
Multiple Sclerosis Journal 2015cited by 503position: middledoi
A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview
Multiple Sclerosis Journal 2015cited by 398position: middledoi

Grants

Household Producer Effects of Rural Diet Transformation
NSF1918324$122,4452020–2024PIRePORTER
Achievement Scholarships in Engineering, Mathematics, and Science
NSF1059891$598,5502011–2016PIRePORTER
High Risk Exploratory Research: The Role of Crises in Migration Outcomes: Rural Oaxacans and Politics in Oaxaca City, Mexico
NSF0706795$26,4982007–2008PIRePORTER
Doctoral Dissertation Improvement Grant: Questioning the Barriers to Economic Self-Reliance: A Micro-ethnographic Investiagtion of African-American Women in Prince George's County
NSF0720262$7,1902007–2009PIRePORTER
CAREER: Transnational Migration and Remittances: A Longitudinal Study of Rural Oaxaca
NSF0096258$213,1322000–2004PIRePORTER
CAREER: Transnational Migration and Remittances: A Longitudinal Study of Rural Oaxaca
NSF9875539$200,0001999–2000PIRePORTER
Instructional Scientific Equipment Program
NSF7511532$1,8001975–1977PIRePORTER

Frequent collaborators

Gary Cutter · Epilepsy Foundation11 papers (2014–2023)Olaf Stüve · Southwestern Medical Center8 papers (2014–2016)Stephen C. Reingold · Brampton Civic Hospital8 papers (2014–2015)Ludwig Kappos · Department of Biomedicine Basel7 papers (2019–2023)Per Soelberg Sørensen · University of Copenhagen7 papers (2014–2015)María Trojano · University of Bari Aldo Moro7 papers (2014–2015)Nadia Reider · Manitoba Health7 papers (2014–2015)Douglas L. Arnold · Montreal Neurological Institute and Hospital6 papers (2019–2023)Bruce Cree · California State University, Bakersfield6 papers (2015–2022)Amit Bar‐Or · University of California System5 papers (2019–2022)Hans‐Peter Hartung · The University of Sydney4 papers (2015–2022)Stephen L. Hauser · University of California, San Francisco4 papers (2015–2025)Xavier Montalbán · Fundació ACE4 papers (2019–2022)Heinz Wiendl · JDSU (United States)4 papers (2019–2025)Lawrence Steinman · Stanford University3 papers (2019–2022)Lana Zhovtis Ryerson · Hackensack Meridian Health3 papers (2019–2023)Eva Havrdová · Université Claude Bernard Lyon 13 papers (2019–2022)Joep Killestein · Palacký University Olomouc3 papers (2019–2023)Gilles Defer · Université Claude Bernard Lyon 13 papers (2019–2023)Gavin Giovannoni · Royal London Hospital for Integrated Medicine3 papers (2019–2023)